SEARCH

SEARCH BY CITATION

References

  • Agata J, Chao L & Chao J (2002). Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension 40, 653659.DOI: 10.1161/01.HYP.0000036035.41122.99
  • Alfie ME, Yang X, Hess F & Carretero OA (1996). Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun 224, 625630.DOI: 10.1006/bbrc.1996.1076
  • Bell RM & Yellon DM (2003). Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 35, 185193.
  • Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash KO, Kuida H & Williams RR (1989). A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 13, 38.
  • Bhoola KD, Figueroa CD & Worthy K (1992). Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44, 180.
  • Bledsoe G, Chao L & Chao J (2003). Kallikrein gene delivery attenuates cardiac remodeling and. promotes neovascularization in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 285, H1479H1488.
  • Bouhnik J, Richoux JP, Huang H, Savoie F, Baussant T, Alhenc-Gelas F & Corvol P (1992). Hypertension in Dahl salt-sensitive rats: biochemical and immunohistochemical studies. Clin Sci 83, 1322.
  • Chao J, Jin L, Chen LM, Chen VC & Chao L (1996). Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hum Gene Ther 7, 901911.
  • Chao J, Stallone JN, Liang Y-M, Chen L-M & Chao L (1997). Kallistatin is a potent new vasodilator. J Clin Invest 100, 1117.
  • Chao J, Tillman DM, Wang MY, Margolius HS & Chao L (1986). Identification of a new tissue kallikrein-binding protein. Biochem J 239, 325331.
  • Chao J, Zhang J, Lin KF & Chao L (1998a). Adenovirus-mediated kallikrein gene delivery attenuates hypertension, cardiac hypertrophy and renal injury in Dahl salt-sensitive rats. Hum Gene Ther 9, 2131.
  • Chao J, Zhang JJ, Lin KF & Chao L (1998b). Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int 54, 12501260.
  • Couture R, Harrisson M, Vianna RM & Cloutier F (2001). Kinin receptors in pain and inflammation. Eur J Pharmacol 429, 161176.
  • Dobrzynski E, Yoshida H, Chao J & Chao L (1999). Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats. Immunopharmacology 44, 5765.DOI: 10.1016/S0162-3109(99)00121-6
  • Elliot R & Nuzum F (1934). Urinary excretion of a depressor substance (kallikrein of Frey and Kraut) in arterial hypertension. Endocrinology 18, 462474.
  • Emanueli C, Bonaria Salis M, Stacca T, Gaspa L, Chao J, Chao L, Pinna A & Madeddu P (2001b). Rescue of Impaired Angiogenesis in spontaneously hypertensive rats by intramuscular human. Hypertension 38, 136141.
  • Emanueli C, Maestri R, Corradi D, Marchione R, Minasi A, Tozzi MG, Salis MB, Straino S, Capogrossi MC, Olivetti G & Madeddu P (1999). Dilated and failing cardiomyopathy in bradykinin B (2) receptor knockout mice. Circulation 100, 23592365.
  • Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Bonaria Salis M, Straino S, Tozzi MG, Smith R, Gaspa L, Bianchini G, Stillo F, Capogrossi MC & Madeddu P (2001a). Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103, 125132.
  • Emanueli C, Salis MB, Chao J, Chao L, Agata J, Lin KF, Munao A, Straino S, Minasi A, Capogrossi MC & Madeddu P (2000). Adenovirus-mediated human tissue kallikrein gene delivery inhibits neointima formation induced by interruption of blood flow in mice. Arterioscler Thromb Vasc Biol 20, 14591466.
  • Emanueli C, Salis MB, Pinna A, Stacca T, Milia AF, Spano A, Chao J, Chao L, Sciola L & Madeddu P (2002). Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. Circulation 106, 993999.
  • Farhy RD, Carretero OA, Ho KL & Scicli AG (1993). Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 72, 12021210.
  • Favaro S, Baggio B, Antonello A, Zen A, Cannella G, Todesco S & Borsatti A (1975). Renal kallikrein content of spontaneously hypertensive rats. Clin Sci Mol Med 49, 6971.
  • Fisher M (2002). Developing therapy for acute ischemic stroke. Therapie 57, 564568.
  • Gavras I & Gavras H (1988). Anti-hormones and blood pressure: bradykinin antagonists in blood pressure regulation. Kidney Int 34, S60S62.
  • Gilboa N, Rudofsky UH, Phillips MI & Magro AM (1989). Modulation of urinary kallikrein and plasma renin activities does not affect established hypertension in the Fawn-Hooded rat. Nephron 51, 6166.
  • Hirawa N, Uehara Y, Suzuki T, Kawabata Y, Numabe A, Gomi T, Ikeda T, Kizuki K & Omata M (1999). Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is a bradykinin B2-receptor-mediated event. Nephron 81, 183193.DOI: 10.1159/000045275
  • Jin L, Zhang JJ, Chao L & Chao J (1997). Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum Gene Ther 8, 17531761.
  • Linz W & Scholkens BA (1992). Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 20, S83S90.
  • Madeddu P, Varoni MV, Demontis MP, Chao J, Simson JA, Glorioso N & Anania V (1997). Kallikrein-kinin system and blood pressure sensitivity to salt. Hypertension 29, 471477.
  • Majima M, Mizogami S, Kuribayashi Y, Katori M & Oh-ishi S (1994). Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats. Hypertension 24, 111119.
  • Marceau F (1995). Kinin B1 receptors: a review. Immunopharmacology 30, 126.DOI: 10.1016/0162-3109(95)00011-H
  • Margolius HS (1989). Tissue kallikreins and kinins regulation and roles in hypertensive and diabetic diseases. Annu Rev Pharmacol Toxicol 29, 343364.DOI: 10.1146/annurev.pa.29.040189.002015
  • Martorana PA, Kettenbach B, Breipohl G, Linz W & Scholkens BA (1990). Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 182, 395396.DOI: 10.1016/0014-2999(90)90301-L
  • Meneton P, Bloch-Faure M, Hagege AA, Ruetten H, Huang W, Bergaya S et al. (2001). Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci U S A 98, 26342639.DOI: 10.1073/pnas.051619598
  • Miao RQ, Agata J, Chao L & Chao J (2002). Kallistatin is a new endogenous inhibitor of angiogenesis and tumor growth. Blood 100, 32453252.
  • Miao RQ, Murakami H, Song Q, Chao L & Chao J (2000). Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery. Circ Res 86, 418424.
  • Murakami H, Miao RQ, Chao L & Chao J (1999a). Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. Immunopharmacology 44, 137143.DOI: 10.1016/S0162-3109(99)00120-4
  • Murakami H, Yayama K, Chao L & Chao J (1998). Human kallikrein gene delivery protects against gentamycin-induced nephrotoxicity in rats. Kidney Int 53, 13051313.DOI: 10.1046/j.1523-1755.1998.00867.x
  • Murakami H, Yayama K, Miao RQ, Wang C, Chao L & Chao J (1999b). Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension 34, 164170.
  • Naicker S, Naidoo S, Ramsaroop R, Moodley D & Bhoola K (1999). Tissue kallikrein and kinins in renal disease. Immunopharmacology 44, 183192.DOI: 10.1016/S0162-3109(99)00089-2
  • Overlack A, Stumpe KO, Kolloch R, Ressel C & Krueck F (1981). Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Results of double blind study. Hypertension 3, I18I21.
  • Overlack A, Stumpe KO, Ressel C, Kolloch R, Zywzok W & Kruck F (1980). Decreased urinary kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension. Klin Wochenschr 58, 3742.DOI: 10.1007/BF01477142
  • Pesquero JB, Araujo RC, Heppenstall PA, Stucky CL, Silva JA, Walther T, Oliveira SM, Pesquero JL, Paiva AC, Calixto JB, Lewin GR & Bader M (2000). Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci U S A 97, 81408145.DOI: 10.1073/pnas.120035997
  • Powers CA, Baer PG & Nasjletti A (1984). Reduced glandular kallikrein-like activity in the anterior pituitary of the New Zealand genetically hypertensive rat. Biochem Biophys Res Commun 119, 689693.
  • Pravenec M, Kren V, Kunes J, Scicli AG, Carretero OA, Simonet L & Kurtz TW (1991). Cosegregation of blood pressure with a kallikrein gene family. Hypertension 17, 242246.
  • Price RG (1982). Urinary enzymes, nephrotoxicity and renal disease. Toxicology 23, 99134.DOI: 10.1016/0300-483X(82)90092-0
  • Regoli D, Rhaleb NE, Drapeau G & Dion S (1990). Kinin receptor subtypes. J Cardiovasc Pharmacol 15, S30S38.
  • Silva JA Jr, Araujo RC, Baltatu O, Oliveira SM, Tschope C, Fink E, Hoffmann S, Plehm R, Chai KX, Chao L, Chao J, Ganten D, Pesquero JB & Bader M (2000). Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J 14, 18581860.
  • Song Q, Chao J & Chao L (1996). High level of circulating human tissue kallikrein induces hypotension in a transgenic mouse model. Clin Exp Hypertens 18, 975993.
  • Song Q, Chao J & Chao L (1997). DNA polymorphisms in the 5(flanking region of human tissue kallikrein gene, (RN96-013). Hum Genet 99, 727734.DOI: 10.1007/s004390050439
  • Song Q, Hunt SC, Zheng D, Williams GH, Chao J & Chao L (2005). A promoter polymorphism of human tissue kallikrein gene is associated with the response of blood pressure to dietary salt restriction. Physiol Genomics (in press).
  • Souza DG, Lomez ESL, Pinho V, Pesquero JB, Bader M, Pesquero JG & Teixeira MM (2004). Role of bradykinin B2 and B1 receptors in the local, remote, and systemic inflammatory responses that follow intestinal ischemia and reperfusion injury. J Immunol 172, 25422548.
  • Uehara Y, Hirawa N, Kawabata Y, Suzuki T, Ohshima N, Oka K, Ikeda T, Goto A, Toyo-oka T, Kizuki K & Omata M (1994). Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension 24, 770778.
  • Wang C, Chao L & Chao J (1995). Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 95, 17101706.
  • Wang C, Chao C, Madeddu P, Chao L & Chao J (1998). Central delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. Biochem Biophys Res Commun 244, 449454.DOI: 10.1006/bbrc.1998.8232
  • Wang D, Chao J & Chao L (1997). Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension 29, 488493.
  • Wang J, Xiong W, Yang Z, Davis T, Dewey MJ, Chao J & Chao L (1994). Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 23, 236243.
  • Wang T, Li H, Zhao C, Chen C, Li J, Chao J, Chao L, Xiao X & Wang DW (2004). Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Ther 11, 13421350.DOI: 10.1038/sj.gt.3302294
  • Wolf WC, Yoshida H, Agata J, Chao L & Chao J (2000). Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int 58, 730739.DOI: 10.1046/j.1523-1755.2000.00219.x
  • Woodley-Miller C, Chao J & Chao L (1989). Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. J Hypertens 7, 865871.
  • Xia CF, Yin H, Borlongan CV, Chao L & Chao J (2004). Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension 43, 452459.DOI: 10.1161/01.HYP.0000110905.29389.e5
  • Xiong W, Chao J & Chao L (1995). Muscle delivery of human tissue kallikrein gene reduces blood pressure in hypertensive rats. Hypertension 25, 715719.
  • Yayama K, Wang C, Chao L & Chao J (1998). Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 31, 11041110.
  • Yin H, Chao L & Chao J (2005). Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-GSK-3 and Akt-Bad-14–3–3 signaling pathways. J Biol Chem 280, 80228030.DOI: 10.1074/jbc.M407179200
  • Yoshida H, Zhang JJ, Chao L & Chao J (2000). Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension 35, 2531.
  • Yu H, Song Q, Freedman BI, Chao J, Chao L, Rich SS & Bowden DW (2002). Association of the tissue kallikrein gene promoter with ESRD and hypertension. Kidney Int 61, 10301039.DOI: 10.1046/j.1523-1755.2002.00198.x
  • Zhang JJ, Bledsoe G, Kato K, Chao L & Chao J (2004). Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int 66, 722732.DOI: 10.1111/j.1523-1755.2004.00794.x
  • Zhang JJ, Chao L & Chao J (1999). Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats. Stroke 30, 19251931.
  • Zhao C, Wang P, Xiao X, Chao J, Chao L, Wang DW & Zeldin DC (2003). Gene therapy with tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension 42, 10261033.DOI: 10.1161/01.HYP.0000097603.55404.35
  • Zhou GX, Chao L & Chao J (1992). Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem 267, 2587325880.
  • Zinner SH, Margolius HS, Rosner B & Kass EH (1978). Stability of blood pressure rank and urinary kallikrein concentration in childhood. Circulation 58, 908915.
  • Zinner SH, Margolius HS, Rosner B, Keiser HR & Kass EH (1976). Familial aggregation of urinary kallikrein concentration in childhood: relation to blood pressure, race and urinary electrolytes. Am J Epidemiol 104, 124132.